Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Long-Acting Agents and Fixed-Dose Combinations for Type 2 Diabetes: U.S. Physician and Payer Opinion on the Benefits of Next-Generation Antidiabetic Therapies | Physician & Payer Forum | US | 2014
Type 2 diabetes is a complex metabolic disorder characterized by a declining ability to produce or utilize insulin. The chronic and progressive nature of the disease, as well as its complications…
Psoriatic Arthritis | Treatment Algorithms | Claims Data Analysis | US | 2014
Psoriatic arthritis (PsA) is an inflammatory joint disease that denotes a heterogeneous group of arthritides that may be present with or without obvious psoriatic lesions; therefore, treatment is…
Nephrology: An Analysis of Erythropoiesis Stimulating Agents in Late Stage Chronic Kidney Disease and Phosphate Binders in Dialysis | Treatment Algorithms | Claims Data Analysis | US | 2014
Chronic kidney disease (CKD) affects approximately 26 million people in the United States. While there are multiple prescription therapies that are available for treating the associated symptoms,…
Gram-Negative Infections: How Will U.S. Payer and Prescriber Receptivity to Novel Antibiotics Shape the Market for These Therapies? | Physician & Payer Forum | US | 2014
Gram-negative infections (GNIs) represent a high-value segment of the antibiotic market and are often treated in the hospital setting. Infections due to Gram-negative pathogens (GNPs) are…
Physician &Crohn’s Disease and Ulcerative Colitis: U.S. Physician and Payer Perspectives on Established and Recently Launched Biologics, Emerging Novel Agents and Biosimilars | Payer Forum | US | 2014
Crohn’s disease (CD) and ulcerative colitis (UC) are two gastrointestinal autoimmune/inflammatory indications that commonly feature treatment with biological therapies. The U.S. CD market…
